Table 4.

Summary of effects of combination treatments on secondary outcomes of 16-, 26-, or 52-week outcomes: Unadjusted and adjusted for percentage heavy drinking days

Secondary outcome variables	Combination treatment effects at 16, and 26 or 52 Weeks
	Week 16 Unadjusted PHDD	Week 16 Adjusted PHDD	Week 26 or 52 Unadjusted PHDD	Week 26 or 52 Adjusted PHDD
Brief Symptom Inventory, global severity	ns	ns	ns	ns
Perceived Stress Scale, totala	N < P*	ns	ns	ns
Percentage days paid for work	ns	ns	ns	ns
SF-12 Physical Health scoreb	N × C*	N × C*	N × C‡	N × C‡
SF-12 Mental Health score	ns	ns	A × N × C*	ns
WHOQOL Physical Health domain	ns	ns	ns	ns
WHOQOL Psychological domain	ns	ns	ns	ns
WHOQOL Social Relationships domain	ns	ns	ns	ns
WHOQOL Environment domaina	ns	ns	C > No C*	C > No C*
		A × C*	A × C†
Craving, obsessive-compulsive total	ns	ns	ns	ns
Percentage days of mutual help meetings	ns	ns	ns	ns

Notes: Mixed-model estimates (lsmeans) are based on a full model that adjusts for clinical center, each treatment effect, all two- and three-way interaction terms, and baseline value of each secondary variable.

^a“<” or “>” defines a main effect in the direction indicated

^bsee Results section for description of N × C^‡ interaction. N = naltrexone, A = acamprosate, C = CBI, P = drug placebo, No C = no CBI. All subjects received medical management. SF-12 = Short Form-12; WHOQOL = World Health Organization Quality of Life; ns = no significant main effects or interactions.

^* p < .05

^† p < .01

^‡ p < .001.